- In March 2025, Olympus Corporation introduced an AI-powered surgical planning tool designed to enhance imaging and machine learning capabilities in diagnosing urological diseases. This tool assists in minimally invasive nephrectomies by accurately assessing the size, location, and shape of tumors, cysts, or other abnormalities, thereby improving surgical precision and patient outcomes
- In April, 2023, Boston Scientific Corp. reported a significant surge in its stock value, attributed to approximately 90 new product launches, including advancements in urology devices. The company's strong performance and optimistic guidance reflect its continued investment in expanding its urology device portfolio
- In December 2023, Cook Medical received premarket approval from the U.S. Food and Drug Administration (FDA) for its Zenith Alpha Thoracic Endovascular Graft. This device is indicated for the endovascular treatment of patients with isolated lesions of the descending thoracic aorta. The Zenith Alpha Thoracic Graft features a lower-profile delivery system, enhancing its suitability for patients with smaller iliac arteries and facilitating easier deployment in tortuous anatomy
- In May 2021, Olympus Corporation introduced the Soltive SuperPulsed Laser System, a next-generation laser technology for urological procedures. This system utilizes superpulsed laser technology to provide enhanced precision and control during treatments for kidney stones and benign prostatic hyperplasia (BPH). The Soltive Laser System offers improved tissue interaction and reduced thermal damage, contributing to better patient outcomes and shorter recovery times
- In May 2021, Teleflex announced that its UroLift Advanced Tissue Control (ATC) System received clearance from the U.S. Food and Drug Administration (FDA). The UroLift ATC System is designed to treat lower urinary tract symptoms due to benign prostatic hyperplasia (BPH) by providing improved tissue manipulation and control during the procedure. This advancement aims to enhance the efficiency and effectiveness of the UroLift System, offering patients a minimally invasive treatment option for BPH
